Alliance Global Group, Invivoscribe Ink Distribution Deal | GenomeWeb

NEW YORK (GenomeWeb) – The Alliance Global Group today announced an exclusive master agreement for the distribution of Invivoscribe Technologies' molecular diagnostics in Alliance's markets.

Based in San Diego, Invivoscribe's products include assays for detecting clonal gene rearrangements, gene translocations, and gene mutations in patients with suspected lymphoproliferations, among other things. It also has CLIA- and CAP-certified clinical reference laboratories in the European Union and the US to perform FLT2 and NPM1 mutation testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.